Jiangsu Recbio Technology Co., Ltd. Class H (HK:2179) has released an update.
Jiangsu Recbio Technology Co., Ltd. has announced its unaudited interim results for the six months ending June 30, 2024, highlighting rapid progress in vaccine development. Key advancements include ongoing Phase III trials for its HPV 9-valent vaccine with expected BLA submission in 2025, completion of Phase I trials for a novel adjuvanted shingles vaccine, and the establishment of a high-standard vaccine production base in Taizhou City. The company is also reallocating its resources in the COVID-19 vaccine project, with no further clinical trials planned for current strains, and adjusting its business direction towards respiratory combination vaccines.
For further insights into HK:2179 stock, check out TipRanks’ Stock Analysis page.
